LigaChem Biosciences Inc.
Financials
Valuation Metrics
LigaChem Biosciences Inc.'s Market Cap is ₩4.1T. At end of 2025 it was ₩6.4T. Ranked #114 of 2,436 in KR market (top 5%), #10 of 1,649 on KOSDAQ (top 0.6%), #9 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 4%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 4.07T KRW | KR#114/2,436 Sec#9/234 |
| Revenue | 125.87B KRW | KR#1,268/2,436 Sec#77/234 |
| Net Income | -151.33B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 652.93B KRW | KR#626/2,436 Sec#34/234 |
| Net Assets | 500.52B KRW | KR#498/2,436 Sec#30/234 |
| Employees | 174 | KR#1,188/2,436 Sec#99/234 |
| Value | ||
| P/B | 8.13x | KR#2,315/2,436 Sec#202/234 |
| P/S | 32.32x | KR#2,354/2,436 Sec#191/234 |
| FCF Yield | -3.14% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -30.23% | KR#2,169/2,436 Sec#173/234 |
| ROA | -23.18% | KR#2,253/2,436 Sec#184/234 |
| Op. Margin | -123.37% | KR#2,325/2,436 Sec#180/234 |
| Revenue Growth | -30.42% | KR#2,177/2,436 Sec#198/234 |
| Earnings Growth | -225.81% | KR#1,515/2,436 Sec#99/234 |
| Financial Health | ||
| Debt Ratio | 30.45% | KR#97/2,436 Sec#12/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | -127.58B KRW | KR#2,158/2,436 Sec#214/234 |
| Cash | 63.48B KRW | KR#641/2,436 Sec#31/234 |
| Current Ratio | 10.12x | KR#101/2,436 Sec#27/234 |
| Performance | ||
| 1Y Return | -19.01% | KR#1,233/2,436 Sec#100/234 |
| 1M Return | -17.80% | KR#2,115/2,436 Sec#211/234 |
| From 52W High | -51.16% | KR#1,249/2,436 Sec#107/234 |
| 1Y MDD | -63.51% | KR#1,612/2,436 Sec#131/234 |
| Trading | ||
| Volume | 570,552 shares | KR#247/2,436 Sec#23/234 |
| Foreign Own. | 12.47% | KR#400/2,436 Sec#36/234 |
| Per Share | ||
| EPS | -3,772 KRW | KR—/2,436 Sec—/234 |
| BPS | 12,705 KRW | KR#783/2,436 Sec#54/234 |
Company Info
LegoChem Biosciences, established in 2006 and headquartered in Yuseong-gu, Daejeon, is a research-oriented pharmaceutical company listed on KOSDAQ in 2013. The company developed the medicinal chemistry-based original Antibody-Drug Conjugate (ADC) technology named ConjuALL, driving global commercialization through ADC anticancer drug research and development and technology transfer. Through "Beyond ADC" research, it focuses on developing bispecific antibody ADCs, immuno-oncology drugs, and combination therapies, while also securing stable revenue from medical device and consumable sales.